Clinuvel Pharmaceuticals Ltd

CUV

Company Profile

  • Business description

    Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.

  • Contact

    535 Bourke Street
    Level 22
    MelbourneVIC3000
    AUS

    T: +61 396604900

    https://www.clinuvel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2025

    Employees

    16

Stocks News & Analysis

stocks

Undervalued ASX listed biotech refocuses

Fair value uneffected by suspended early-stage clinical trials.
funds

10 reasons many fund managers are now blank spaces

It looks easy from the outside, but asset management is a tough game. Winners can win big, but there are far more strugglers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,399.8030.500.36%
CAC 407,626.8470.08-0.91%
DAX 4023,115.96133.69-0.58%
Dow JONES (US)40,863.9034.900.09%
FTSE 1008,559.3338.09-0.44%
HKSE22,691.8829.170.13%
NASDAQ17,524.04165.62-0.94%
Nikkei 22536,779.6651.03-0.14%
NZX 50 Index12,496.8975.800.61%
S&P 5005,582.7924.12-0.43%
S&P/ASX 2008,178.3026.900.33%
SSE Composite Index3,342.6726.550.80%

Market Movers